PMID- 21585705
OWN - NLM
STAT- MEDLINE
DCOM- 20110801
LR  - 20151119
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
VI  - 7 Suppl 2
DP  - 2011 Jun
TI  - Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed 
      for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.
PG  - 22-33
LID - 10.1111/j.1743-7563.2011.01399.x [doi]
AB  - AIMS: The aim of this analysis is to investigate the mean incremental costs and 
      life expectancy associated with two first-line treatments for advanced 
      non-squamous non-small cell lung cancer (NSCLC) in Korea and Taiwan; bevacizumab 
      plus cisplatin and gemcitabine (BevCG) and cisplatin plus pemetrexed (CP). 
      METHODS: A health economic (area under curve) model with three health states was 
      developed to assess health outcomes (life-years gained [LYG]), direct costs, and 
      incremental cost-effectiveness ratio (ICER). Progression-free survival (PFS) and 
      overall survival (OS) were derived from randomized clinical trials and used in an 
      indirect comparison in order to estimate their cost effectiveness. A life-time 
      horizon was used. Costs and outcomes were discounted yearly by 5% in Korea and by 
      3% in Taiwan. RESULTS: The incremental LYG for the BevCG patients compared with 
      patients treated with CP were 1.10 (13.2 months) in Korea and 1.19 (14.3 months) 
      in Taiwan. The incremental costs were 37,439,968 ($ 33,322) in Korea and NT$ 
      1,910,615 ($ 64,541) in Taiwan. The incremental cost-effectiveness ratio was 
      34,064,835 ($ 30,318) in Korea and NT$ 1,607,960 ($ 54,317) in Taiwan. The inputs 
      tested in one-way sensitivity analyses had very little impact on the overall cost 
      effectiveness. CONCLUSION: This analysis shows that BevCG is more costly but is 
      also associated with additional life-years in Korea and Taiwan. The ICER per LYG 
      suggests that BevCG is a cost-effective therapy when compared to CP for patients 
      with advanced NSCLC in Korea and Taiwan.
CI  - (c) 2011 Blackwell Publishing Asia Pty Ltd.
FAU - Ahn, Myung-Ju
AU  - Ahn MJ
AD  - Section of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 
      silkahn@skku.edu
FAU - Tsai, Chun-Ming
AU  - Tsai CM
FAU - Hsia, Te-Chun
AU  - Hsia TC
FAU - Wright, Elaine
AU  - Wright E
FAU - Chang, John Wen-Cheng
AU  - Chang JW
FAU - Kim, Heung Tae
AU  - Kim HT
FAU - Kim, Joo-Hang
AU  - Kim JH
FAU - Kang, Jin Hyoung
AU  - Kang JH
FAU - Kim, Sang-We
AU  - Kim SW
FAU - Bae, Eun-Jin
AU  - Bae EJ
FAU - Kang, Mijeong
AU  - Kang M
FAU - Lister, Johanna
AU  - Lister J
FAU - Walzer, Stefan
AU  - Walzer S
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Glutamates)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 5Z93L87A1R (Guanine)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/administration & dosage/*economics/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/*economics/*therapeutic use
MH  - Bevacizumab
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/economics
MH  - Cisplatin/administration & dosage
MH  - Cost-Benefit Analysis
MH  - Disease-Free Survival
MH  - Female
MH  - Glutamates/administration & dosage
MH  - Guanine/administration & dosage/analogs & derivatives
MH  - Humans
MH  - Korea
MH  - Lung Neoplasms/*drug therapy/economics
MH  - Male
MH  - Middle Aged
MH  - Pemetrexed
MH  - Survival Analysis
MH  - Taiwan
EDAT- 2011/05/21 06:00
MHDA- 2011/08/02 06:00
CRDT- 2011/05/19 06:00
PHST- 2011/05/19 06:00 [entrez]
PHST- 2011/05/21 06:00 [pubmed]
PHST- 2011/08/02 06:00 [medline]
AID - 10.1111/j.1743-7563.2011.01399.x [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:22-33. doi: 
      10.1111/j.1743-7563.2011.01399.x.